首页> 外文期刊>Nature >Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity
【24h】

Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity

机译:替代脂肪酸去饱和途径增加癌症可塑性的证据

获取原文
获取原文并翻译 | 示例
       

摘要

Most tumours have an aberrantly activated lipid metabolism(1,2) that enables them to synthesize, elongate and desaturate fatty acids to support proliferation. However, only particular subsets of cancer cells are sensitive to approaches that target fatty acid metabolism and, in particular, fatty acid desaturation(3). This suggests that many cancer cells contain an unexplored plasticity in their fatty acid metabolism. Here we show that some cancer cells can exploit an alternative fatty acid desaturation pathway. We identify various cancer cell lines, mouse hepatocellular carcinomas, and primary human liver and lung carcinomas that desaturate palmitate to the unusual fatty acid sapienate to support membrane biosynthesis during proliferation. Accordingly, we found that sapienate biosynthesis enables cancer cells to bypass the known fatty acid desaturation pathway that is dependent on stearoyl-CoA desaturase. Thus, only by targeting both desaturation pathways is the in vitro and in vivo proliferation of cancer cells that synthesize sapienate impaired. Our discovery explains metabolic plasticity in fatty acid desaturation and constitutes an unexplored metabolic rewiring in cancers.
机译:大多数肿瘤具有异常激活的脂质代谢(1,2),使它们能够合成,延长和去饱和脂肪酸以支持增殖。但是,只有癌细胞的特定子集对靶向脂肪酸代谢特别是脂肪酸去饱和的方法敏感(3)。这表明许多癌细胞的脂肪酸代谢中含有未开发的可塑性。在这里,我们显示了一些癌细胞可以利用其他脂肪酸去饱和途径。我们确定了各种癌细胞系,小鼠肝细胞癌以及原发性人类肝癌和肺癌,它们使棕榈酸酯去饱和到异常的脂肪酸sapienate,从而在增殖过程中支持膜的生物合成。因此,我们发现智人生物合成使癌细胞能够绕过依赖于硬脂酰辅酶A去饱和酶的已知脂肪酸去饱和途径。因此,仅通过靶向两个去饱和途径,合成了智人的癌细胞的体外和体内增殖受到损害。我们的发现解释了脂肪酸去饱和中的代谢可塑性,并构成了癌症中未经探索的代谢重排。

著录项

  • 来源
    《Nature》 |2019年第7744期|403-406|共4页
  • 作者单位

    KU Leuven VIB, Ctr Canc Biol, Lab Cellular Metab & Metab Regulat, Leuven, Belgium|Katholieke Univ Leuven, Dept Oncol, Lab Cellular Metab & Metab Regulat, Leuven, Belgium|Leuven Canc Inst LKI, Leuven, Belgium;

    KU Leuven VIB, Ctr Canc Biol, Lab Cellular Metab & Metab Regulat, Leuven, Belgium|Katholieke Univ Leuven, Dept Oncol, Lab Cellular Metab & Metab Regulat, Leuven, Belgium|Leuven Canc Inst LKI, Leuven, Belgium;

    KU Leuven VIB, Ctr Canc Biol, Lab Cellular Metab & Metab Regulat, Leuven, Belgium|Katholieke Univ Leuven, Dept Oncol, Lab Cellular Metab & Metab Regulat, Leuven, Belgium|Leuven Canc Inst LKI, Leuven, Belgium|Vrije Univ Brussel, Lab Cellular & Mol Immunol, Brussels, Belgium|Ctr Inflammat Res VIB, Myeloid Cell Immunol Lab, Brussels, Belgium;

    KU Leuven VIB, Ctr Canc Biol, Lab Cellular Metab & Metab Regulat, Leuven, Belgium|Katholieke Univ Leuven, Dept Oncol, Lab Cellular Metab & Metab Regulat, Leuven, Belgium|Leuven Canc Inst LKI, Leuven, Belgium;

    Tsukishima Foods Ind, Tokyo, Japan|Fukushima Univ, Fac Food & Agr Sci, Cluster Agr Sci, Fukushima, Japan;

    Leuven Canc Inst LKI, Dept Oncol, Lab Lipid Metab & Canc, Leuven, Belgium;

    Leuven Canc Inst LKI, Dept Oncol, Lab Lipid Metab & Canc, Leuven, Belgium;

    KU Leuven VIB, Ctr Canc Biol, Lab Cellular Metab & Metab Regulat, Leuven, Belgium|Katholieke Univ Leuven, Dept Oncol, Lab Cellular Metab & Metab Regulat, Leuven, Belgium|Leuven Canc Inst LKI, Leuven, Belgium;

    KU Leuven VIB, Ctr Canc Biol, Lab Cellular Metab & Metab Regulat, Leuven, Belgium|Katholieke Univ Leuven, Dept Oncol, Lab Cellular Metab & Metab Regulat, Leuven, Belgium|Leuven Canc Inst LKI, Leuven, Belgium;

    Univ Oxford, Churchill Hosp, Radcliffe Dept Med, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England;

    Univ Oxford, Churchill Hosp, Radcliffe Dept Med, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England;

    Ludwig Maximilians Univ Munchen, Fac Med, Inst Pathol, Max Eder Res Grp Pediat Sarcoma Biol, Munich, Germany;

    KU Leuven VIB, Ctr Canc Biol, Lab Cellular Metab & Metab Regulat, Leuven, Belgium|Katholieke Univ Leuven, Dept Oncol, Lab Cellular Metab & Metab Regulat, Leuven, Belgium|Leuven Canc Inst LKI, Leuven, Belgium;

    KU Leuven VIB, Ctr Canc Biol, Lab Cellular Metab & Metab Regulat, Leuven, Belgium|Katholieke Univ Leuven, Dept Oncol, Lab Cellular Metab & Metab Regulat, Leuven, Belgium|Leuven Canc Inst LKI, Leuven, Belgium;

    Ludwig Maximilians Univ Munchen, Fac Med, Inst Pathol, Max Eder Res Grp Pediat Sarcoma Biol, Munich, Germany;

    Katholieke Univ Leuven, Dept Dev & Regenerat, Stem Cell Inst, Leuven, Belgium;

    Bio Imaging Core VIB, Leuven, Belgium|KU Leuven VIB, KU Leuven Ctr Brain & Dis Res, Leuven, Belgium|Katholieke Univ Leuven, Dept Neurosci, Mol Neurobiol, Leuven, Belgium;

    Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA;

    UT Southwestern, Childrens Med Ctr Res Inst, Dallas, TX USA;

    Francis Crick Inst, London, England;

    Bayer AG, Res & Dev, Pharmaceut, Berlin, Germany;

    NYU, Smilow Res Ctr, Langone Med Ctr, Perlmutter Canc Ctr, New York, NY USA;

    KU Leuven VIB, Ctr Canc Biol, Lab Cellular Metab & Metab Regulat, Leuven, Belgium|Katholieke Univ Leuven, Dept Oncol, Lab Cellular Metab & Metab Regulat, Leuven, Belgium|Leuven Canc Inst LKI, Leuven, Belgium;

    KU Leuven VIB, Ctr Canc Biol, Lab Cellular Metab & Metab Regulat, Leuven, Belgium|Katholieke Univ Leuven, Dept Oncol, Lab Cellular Metab & Metab Regulat, Leuven, Belgium|Leuven Canc Inst LKI, Leuven, Belgium;

    Bayer AG, Res & Dev, Pharmaceut, Berlin, Germany;

    Bayer AG, Res & Dev, Pharmaceut, Berlin, Germany;

    Catholic Univ Louvain, IREC, Lab Pediat Hepatol & Cell Therapy, Brussels, Belgium|Clin Univ St Luc, Brussels, Belgium;

    Bayer AG, Res & Dev, Pharmaceut, Berlin, Germany;

    Vrije Univ Brussel, Lab Cellular & Mol Immunol, Brussels, Belgium|Ctr Inflammat Res VIB, Myeloid Cell Immunol Lab, Brussels, Belgium;

    Catholic Univ Louvain, IREC, Lab Pediat Hepatol & Cell Therapy, Brussels, Belgium|Clin Univ St Luc, Brussels, Belgium;

    Tokyo Univ Marine Sci & Technol, Dept Food Sci & Technol, Tokyo, Japan;

    NYU, Smilow Res Ctr, Langone Med Ctr, Perlmutter Canc Ctr, New York, NY USA;

    Katholieke Univ Leuven, Dept Dev & Regenerat, Stem Cell Inst, Leuven, Belgium;

    Katholieke Univ Leuven, Dept Cellular & Mol Med, Lab Prot Phosphorylat & Prote, Leuven, Belgium;

    Bio Imaging Core VIB, Leuven, Belgium|KU Leuven VIB, KU Leuven Ctr Brain & Dis Res, Leuven, Belgium|Katholieke Univ Leuven, Dept Neurosci, Mol Neurobiol, Leuven, Belgium;

    Francis Crick Inst, London, England;

    Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA;

    UT Southwestern, Childrens Med Ctr Res Inst, Dallas, TX USA|UT Southwestern Med Ctr, Howard Hughes Med Inst, Dallas, TX USA;

    Leuven Canc Inst LKI, Dept Oncol, Lab Lipid Metab & Canc, Leuven, Belgium;

    Univ Oxford, Churchill Hosp, Radcliffe Dept Med, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England;

    Katholieke Univ Leuven, Dept Hepatol, Leuven, Belgium|Katholieke Univ Leuven, Dept Chron Dis Metab & Ageing, Leuven, Belgium;

    Katholieke Univ Leuven, Dept Hepatol, Leuven, Belgium|Katholieke Univ Leuven, Dept Digest Oncol, Leuven, Belgium;

    Bayer AG, Res & Dev, Pharmaceut, Berlin, Germany;

    Bayer AG, Res & Dev, Pharmaceut, Berlin, Germany;

    Ludwig Maximilians Univ Munchen, Fac Med, Inst Pathol, Max Eder Res Grp Pediat Sarcoma Biol, Munich, Germany|Ludwig Maximilians Univ Munchen, Inst Pathol, Fac Med, Munich, Germany|German Canc Consortium DKTK, Partner Site Munich, Munich, Germany|German Canc Res Ctr, Heidelberg, Germany;

    KU Leuven VIB, Ctr Canc Biol, Lab Cellular Metab & Metab Regulat, Leuven, Belgium|Katholieke Univ Leuven, Dept Oncol, Lab Cellular Metab & Metab Regulat, Leuven, Belgium|Leuven Canc Inst LKI, Leuven, Belgium;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 04:10:10

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号